Ideaya Biosciences, Inc. (NASDAQ: IDYA) is an innovative precision medicine oncology company headquartered in South San Francisco, California, dedicated to advancing targeted therapies that leverage molecular diagnostics to improve patient outcomes. The company focuses on synthetic lethality, developing treatments that selectively target cancer cells with specific genetic profiles, addressing critical unmet needs in oncology. With a strong emphasis on advanced biomarker analysis and a comprehensive drug development pipeline, Ideaya is well-positioned to enhance personalized cancer treatment strategies and drive significant advancements in the field.